Arecor Therapeutics plc (LON:AREC) Insider Buys £9,906.19 in Stock

Arecor Therapeutics plc (LON:AREC) insider Sarah Jennifer Howell acquired 21,077 shares of the company’s stock in a transaction dated Monday, May 19th. The shares were purchased at an average cost of GBX 47 ($0.63) per share, for a total transaction of £9,906.19 ($13,266.63).

Arecor Therapeutics Price Performance

Shares of LON AREC opened at GBX 44.17 ($0.59) on Wednesday. The stock has a market capitalization of £16.68 million, a price-to-earnings ratio of -1.56 and a beta of -0.18. Arecor Therapeutics plc has a 12 month low of GBX 35.40 ($0.47) and a 12 month high of GBX 170 ($2.28). The firm’s 50 day simple moving average is GBX 41.15 and its 200-day simple moving average is GBX 56.33. The company has a debt-to-equity ratio of 5.51, a current ratio of 1.37 and a quick ratio of 6.24.

Arecor Therapeutics (LON:AREC) last issued its quarterly earnings data on Tuesday, April 22nd. The company reported GBX (0.31) ($0.00) EPS for the quarter. Arecor Therapeutics had a negative return on equity of 118.67% and a negative net margin of 176.89%. Analysts expect that Arecor Therapeutics plc will post -0.35 EPS for the current year.

Arecor Therapeutics Company Profile

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products.